The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-09. Anything still debated is marked as such rather than presented as settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
All living organisms produce substances to defend themselves from being eaten. However, the term "poison" typically refers to substances that are toxic to humans. Substances that are toxic primarily to pathogens and not to humans are generally classified as antibiotics. For instance, Penicillium chrysogenum produces compounds toxic to bacteria, but not to humans, making them effective as antibacterial drugs. Similarly, human antimicrobial peptides, which are toxic to viruses, fungi, bacteria, and cancerous cells; are considered part of the innate immune system. In nuclear physics, the term nuclear poison refers to a substance that absorbs neutrons and interferes with a nuclear reaction. Substances classified as environmentally hazardous are not always poisonous, and vice versa. For example, wastewater from food processing, such as potato juice or milk; can be environmentally damaging by depleting oxygen in aquatic ecosystems (leading to eutrophication), but it poses no direct toxic threat to humans and is not considered a poison. From a biological standpoint, virtually any substance can be toxic in sufficient quantity. Even something as essential as water can be fatal when consumed in excessive amounts; a condition known as water intoxication. Many drugs used in medicine, such as fentanyl, have a median lethal dose (LD50) only slightly higher than their effective dose (ED50), highlighting the thin margin between therapeutic benefit and toxicity. Some classification systems differentiate between lethal substances with therapeutic value and those without.
=== March === 1 March 35-year-old Marcus Osborne is given a whole life order, the most severe possible sentence available in England and Wales, for the "sadistic" murders of Steven Harnett and Katie Higton. He receives a further 10-year sentence for the rape and false imprisonment of another woman who was present at the scene, who cannot be named for legal reasons. 29-year-old Joshua Jacques is sentenced to a minimum of 46 years in prison for murdering his girlfriend and three of her family members in a "sacrifice" at their home in Bermondsey, south London, in April 2022. The Met Office reports that England and Wales had their warmest February on record this year, with an average of 7.5 °C recorded for England and 6.9 °C for Wales. Scientists at the Centre for Environment, Fisheries and Aquaculture Science announce the discovery of a new species of sea slug off the southwest coast of England. 2 March The 2024 BRIT Awards take place. Northumberland National Park announces that the Sycamore Gap tree which was illegally felled last September is to go on public display. 4 March The Princess of Wales is photographed for the first time since her surgery, with US celebrity news site TMZ publishing a photo of the princess riding as a passenger in a car being driven by her mother near Windsor Castle. Rumours and conspiracy theories over Catherine's whereabouts have surfaced in recent weeks as she hasn't been seen in public since late December. Cadbury celebrate their 200th anniversary.
== Works == Simulated distillation of high-boiling petroleum fractions by capillary supercritical fluid chromatography and vacuum thermal gravimetric analysis, with Herbert E. Schwartz, Mieczyslaw M. Boduszynski, and Fu Su in Analytical Chemistry (journal), May 15, 1987
== History == Sarepta started in Corvallis, Oregon on January 1, 1980 and was originally named Antivirals Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time, the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit and had not yet developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won an $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time, the company had completed its headquarters move to Bothell. In 2012, the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016. In June 2017, Sarepta Therapeutics appointed former Allergan executive Doug Ingram as its new CEO to replace Edward Kaye who had announced plans to step down earlier that year.
Sources: en.wikipedia.org
Realizing he needs to keep the youth formula out of Buddy's hands, Sherman stores it at his parents' home. Sexually frustrated due to his age and impotence, Cletus accidentally drinks some of the youth formula. He goes to a nightclub and attempts to seduce his wife and Sherman's mother, Anna, but she is disgusted. Buddy witnesses Cletus changing and realizes that the youth formula is being stored in the Klump household. Meanwhile, Sherman's condition causes him to humiliate himself in front of Denise's parents, concerning her. While Sherman's grandmother, Ida Mae Jensen and Anna are organizing a bachelorette party for Denise, Buddy steals some of the youth formula from the Klump household, filling the vial the rest of the way with fertilizer. This sabotage causes chaos at a demonstration the next day as Petey, the male hamster Sherman uses to demonstrate the formula, mutates into a giant monster who rapes Richmond as he is trying to escape under a fur coat, as Petey confuses him for Molly, the female hamster that escaped during the event. The traumatized and furious Richmond fires Sherman, who soon learns from Jason that his brain's deterioration has worsened, so he decides to break up with Denise. Cletus reconciles with Anna and consoles a depressed Sherman, and inadvertently gives him the solution to regaining his intelligence: getting Buddy Love back into his DNA. Sherman quickly works on a new, more potent formula while his mental faculties allow him. Richmond confronts him about Buddy's actions, believing that they are working together.
Effects of ROS on cell metabolism are well documented in a variety of species. These include not only roles in apoptosis (programmed cell death) but also positive effects such as the induction of host defence genes and mobilization of ion transporters. This implicates them in control of cellular function. In particular, platelets involved in wound repair and blood homeostasis release ROS to recruit additional platelets to sites of injury. These also provide a link to the adaptive immune system via the recruitment of leukocytes. Reactive oxygen species are implicated in cellular activity to a variety of inflammatory responses including cardiovascular disease. They may also be involved in hearing impairment via cochlear damage induced by elevated sound levels, in ototoxicity of drugs such as cisplatin, and in congenital deafness in both animals and humans. ROS are also implicated in mediation of apoptosis or programmed cell death and ischaemic injury. Specific examples include stroke and heart attack. In general, the harmful effects of reactive oxygen species on the cell are the damage of DNA or RNA, oxidation of polyunsaturated fatty acids in lipids (lipid peroxidation), oxidation of amino acids in proteins, and oxidative deactivation of specific enzymes by oxidation co-factors. They play a role in causing dangerous genetic mutations.
=== Food === Several foods, creams, and toppings all contain a variety of caseinates. Sodium caseinate acts as a greater food additive for stabilizing processed foods; however, companies could opt to use calcium caseinate to increase calcium content and decrease sodium levels in their products.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.